Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Beam Therapeutics Inc

Current price
24.22 USD -0.32 USD (-1.30%)
Last closed 24.32 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 001 806 080 USD
Yield for 12 month -24.08 %
21.11.2021 - 28.11.2021

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Address: 238 Main Street, Cambridge, MA, United States, 02142-1016

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

48.67 USD

P/E ratio

Dividend Yield

Current Year

+377 709 000 USD

Last Year

+60 920 000 USD

Current Quarter

+7 410 000 USD

Last Quarter

+316 192 000 USD

Current Year

+357 697 000 USD

Last Year

+38 343 000 USD

Current Quarter

+1 979 000 USD

Last Quarter

+310 830 000 USD

Key Figures BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -160 892 992 USD
Operating Margin TTM -1405.29 %
PE Ratio
Return On Assets TTM -8.44 %
PEG Ratio
Return On Equity TTM -16.09 %
Wall Street Target Price 48.67 USD
Revenue TTM 360 911 008 USD
Book Value 11.58 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -69.4 %
Dividend Yield
Gross Profit TTM -250 674 000 USD
Earnings per share -1.6 USD
Diluted Eps TTM -1.6 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -37.33 %

Dividend Analytics BEAM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.9128
Price Sales TTM 5.6059
Enterprise Value EBITDA -7.0312
Price Book MRQ 2.1577

Financials BEAM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BEAM

For 52 weeks

16.95 USD 49.5 USD
50 Day MA 26.66 USD
Shares Short Prior Month 14 017 683
200 Day MA 26.65 USD
Short Ratio 9.42
Shares Short 14 584 632
Short Percent 23.22 %

Dynamics of changes in the value of assets




430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds



14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics